Market Access News | pharmaphorum

News

AbbVie bids to join the BCMA crowd with etentamig

AbbVie has filed for FDA approval of its BCMAxCD3 bispecific etentamig in multiple myeloma, a key pillar of its expansion into oncology.

News

Bayer gets first approval for stroke drug asundexian

Bayer's oral Factor XIa inhibitor asundexian has been cleared in its first market, China, for secindary stroke prevention.

News

US Treasury proposes curbs on Chinese biotech deals

China has emerged as a major source of drug candidates for pharma groups, but a new proposal by the US Treasury could slam the brakes on future deals.

News

Five AI tools to spot prostate cancer backed for NHS use

NICE has backed temporary NHS use of five AI tools that can help detect prostate cancer on MRI scans, while more evidence on their value is gathered.

News

AZ grabs FDA nod for Ultomiris in rare kidney disease IgAN

AstraZeneca has staked a claim to the increasingly crowded IgAN market with an accelerated approval from the FDA for Ultomiris, its fifth indication.

News

Despite US policy changes, drug prices stay stubbornly high

US policy changes designed to curb drug prices seem ineffective, as the annual cost of new medicines still exceeds $250,000, curbing patient access.

AbbVie bids to join the BCMA crowd with etentamig

Bayer gets first approval for stroke drug asundexian

US Treasury proposes curbs on Chinese biotech deals

Five AI tools to spot prostate cancer backed for NHS use

AZ grabs FDA nod for Ultomiris in rare kidney disease IgAN

Despite US policy changes, drug prices stay stubbornly high

Lilly partners with Hims & Hers on obesity drug sales

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks